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Correct definition of the level of risk of invasive fungal infections is the first step in improving the targeting of preventive
strategies. We investigated the potential relationship between pre-hospitalization exposure to sources of fungi and the devel-
opment of invasive fungal infections in adult patients with newly diagnosed acute myeloid leukemia after their first course
of chemotherapy. From January 2010 to April 2012, all consecutive acute myeloid leukemia patients in 33 Italian centers were
prospectively registered. Upon first admission, information about possible pre-chemotherapy risk factors and environmental
exposure was collected. We recorded data regarding comorbid conditions, employment, hygienic habits, working and living
environment, personal habits, hobbies, and pets. All invasive fungal infections occurring within 30 days after the first course
of chemotherapy were recorded. Of the 1,192 patients enrolled in this study, 881 received intensive chemotherapy and were
included in the present analysis. Of these, 214 developed an invasive fungal infection, including 77 proven/probable cases
(8.7%). Of these 77 cases, 54 were proven/probable invasive mold infections (6.1%) and 23 were proven yeast infections
(2.6%). Upon univariate analysis, a significant association was found between invasive mold infections and age, perform-
ance status, diabetes, chronic obstructive pulmonary disease, smoking, cocaine use, job, hobbies, and a recent house reno-
vation. Higher body weight resulted in a reduced risk of invasive mold infections. Multivariate analysis confirmed the role
of performance status, job, body weight, chronic obstructive pulmonary disease, and house renovation. In conclusion, sev-
eral hospital-independent variables could potentially influence the onset of invasive mold infections in patients with acute
myeloid leukemia. Investigation of these factors upon first admission may help to define a patient’s risk category and
improve targeted prophylactic strategies. (Clinicaltrial.gov: NCT01315925)
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ABSTRACT
Introduction
Invasive fungal infections in patients with hematologic
malignancies have increased during the last few years, par-
ticularly in patients with acute myeloid leukemia (AML).1,2
These complications are associated with a high risk of
infection-related death; furthermore, experiencing an inva-
sive fungal infection may affect the outcome of the hema-
tologic malignancy.3 For these reasons, during the last few
years, much effort has been devoted to optimizing the pre-
vention of invasive fungal infections for those patients in
high-risk categories.4-6 Antifungal prophylaxis with newer
azoles (e.g., posaconazole) has shown good efficacy,
although newer azoles cost more and confer a higher risk
of resistance.7
Stratifying risk for invasive fungal infection is the logical
first step in identifying patients who would most likely
benefit from antifungal prophylaxis, more intensive moni-
toring or early treatment.  A patient’s risk level is the result
of multiple factors, such as the presence of an underlying
malignancy (including therapies and immune status), fac-
tors intrinsic to the patient (genetic pattern, comorbidities,
performance status) and the environment (in or out of the
hospital).8 The role of air concentrations of fungi during
hospitalization has been investigated in several studies,
and it has been shown to correlate with the onset of
aspergillosis in susceptible patients.9,10 In contrast, the role
of hospital-independent exposure to sources of fungi (e.g.,
in the home or in the work place) is not known. 
The aim of the present study was to evaluate the poten-
tial relationship between pre-chemotherapy risk factors
and the onset of invasive fungal infection after the first
induction treatment.
Methods
The present prospective study was conducted in 33 hematol-
ogy wards of tertiary care centers or university hospitals located
throughout Italy from January 1st, 2010 to April 30th, 2012. All
adult patients with newly diagnosed AML were consecutively
included in the registry and monitored. A minimum follow-up of
90 days after completion of the first cycle of chemotherapy was
required. The last patient entered the trial on April 30th, 2012, and
the last follow-up was completed on July 31st, 2012. The ethics
committee of each participating site approved the use of the
SEIFEM registry. 
This was a non-interventional study. Accordingly, the enroll-
ment of a patient had no impact on the standard clinical practice
of the participating hematology units. The data were entered
prospectively into case report forms that were divided into two
parts. 
The first part was compiled at the time of first admission to the
hematology ward and included questions about AML subtype
and treatment, demographic data and personal history before hos-
pitalization. In particular, the following information was collect-
ed: age, gender, race, body weight, comorbid conditions [diabetes,
chronic obstructive pulmonary disease (COPD), renal or hepatic
failure], performance status, job, hobbies, workplace, home (area
of residence, type of house, pets/poultry ownership, exposure to
plants or fireplace) and personal habits (alcohol, use of illicit
drugs). The type of hospital (teaching versus non-teaching) and the
season of diagnosis were also included in the analysis.
The second part of the case report form was compiled on the
30th day after the end of the first cycle of chemotherapy, and it col-
lected data regarding post-chemotherapy factors, particularly the
level and duration of neutropenia, mucosal damage, vomiting,
diarrhea, the presence of medical devices (e.g., urinary catheter,
central venous catheter) and antifungal prophylaxis. Antifungal
prophylaxis was given according to local clinical practice, and
none of the analyzed pre-hospital risk factor was used a priori as a
trigger for prescription.  
The diagnostic work-up in the cases of fever was similar at all
participating centers and included the following tests: nasal, pha-
ryngeal, and rectal swabs at the time of admission; blood cultures
and chest radiography at onset of fever; galactomannan assays
twice weekly and a chest computed tomography (CT) scan on the
fourth to seventh day of fever. Additional examinations (e.g.,
abdominal ultrasound scan, sinus or brain CT, skin biopsy, bron-
choalveolar lavage, or fundus examination) were performed when
clinically indicated.  
The presence of invasive fungal infection was assessed within
the first 30 days after chemotherapy had ended, according to cur-
rent EORTC criteria.11
Definitions
Various terms were defined before data analysis.
Neutropeniawas defined as an absolute neutrophil count of
<500 cells/mm3. Neutropenia was considered prolonged if
the duration was 10 days and severe if the absolute neu-
trophil count was <100 cells/mm3. Mucositis was graded
according to the World Health Organization (WHO).12High
risk jobs included those employments more likely to expose
the patient to fungal spores, such as construction work,
farming, gardening, being a florist shop employee, and
forestry work.13 High risk hobbies included those activities
that were more likely to expose the participants to fungal
spores, such as hunting, gardening, fishing, and hiking.13
Being overweight was defined as having a body mass index
≥30 kg/m2.14 Performance status was graded according to the
Eastern Cooperative Oncology Group scale.15 Invasive fun-
gal infectionswere classified according to the 2008 European
Organization for Research and Treatment of
Cancer/Mycoses Study Group (EORTC/MSG) criteria.11
Patients with proven/probable mold infections were
termed “mold cases”. Patients with possible mold infections
were considered to have insufficient evidence of infection
and were excluded from the analysis. Patients with proven
yeast infections were termed “yeast cases”. Patients without
any evidence of invasive fungal infection were termed
“controls” and were compared to both the yeast and mold
cases (Figure 1).
Statistical analysis
Values are expressed as the mean ± standard deviation or medi-
an (range) (continuous variables) or as a percentage of the group
from which they were derived (categorical variables). Continuous
variables were compared using the Student t-test for normally dis-
tributed variables or the Mann-Whitney U test for non-normally
distributed variables. Categorical variables were evaluated using
the χ2 test or the two-tailed Fisher exact test. Variables associated
with the onset of an invasive fungal infection in univariate analy-
sis (P≤0.10) were included in a logistic regression analysis, and a
backward stepwise approach was used to identify those factors
independently associated with the onset the infection. The area
under the receiver-operator characteristics (ROC) curve was calcu-
lated for the predictive model. A P-value less than 0.05 was con-
sidered statistically significant. All statistical analyses were per-
formed with the Intercooled Stata software program, version 11
for Windows (StataCorp, College Station, TX, USA).  
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Results 
Over a 28-month period, 1,192 adult patients with newly
diagnosed AML from 33 participating centers were enrolled
in this study [male 48.8%, median age 58 years (interquartile
range, 47-66 years)]. Of these, 205 patients received only
low-dose antineoplastic therapies or palliative treatments
and were excluded from the present analysis (Figure 1).
Another 106 patients were diagnosed with promyelocytic
leukemia and were also excluded. The present analysis
focuses on the 881 AML patients who received conventional
intensive chemotherapy. 
Among the 712 evaluable patients who were treated with
systemic prophylaxis, the majority received posaconazole
prophylaxis (n=439, 61.7%); the remaining patients received
either fluconazole (n=81, 11.4%), or itraconazole (n=149,
20.9%) or other drugs (n=19, 2.7%). 
Over a 28-month period, 214 cases of invasive fungal
infection were recorded (incidence 24.3%); 23 were invasive
yeast infections (incidence 2.6%), while the other 191 cases
were attributed to molds (incidence 21.5%). The majority of
these cases were possible mold infections (n=137, 71.7%;
incidence 15.5%), while the remaining 54 cases were classi-
fied as probable/proven invasive mold infections (28.3%,
incidence 6.1%). In particular, seven cases were classified as
proven invasive mold infections.
Mold cases
Fifty-four patients with proven/probable invasive mold
infections (mold cases) were compared to 667 controls
(Figure 1). Mold cases were more often older than 50 years
(83% versus 67%, P=0.015) and had a poorer performance
status at the time of admission (Table 1A). Higher body
weight was found to reduce the risk of invasive mold infec-
tion. No differences were found with regards to patients’
race. Similarly, neither the type of hospital (teaching versus
non-teaching) nor the season was significant. 
The frequency of therapy-related AML was similar
between cases and controls (20.4% versus 25.5%, P=0.4). A
fludarabine-containing chemotherapeutic regimen did not
appear to represent an additional risk factor (Table 1A).
Both diabetes and COPD were more frequent in mold cases
than in the controls, while the frequency of chronic renal
failure and liver disease was similar between the two
groups.  
Data regarding personal habits and working and living
environment are reported in Table 1B. Cigarette smoking
and cocaine abuse were associated with invasive mold infec-
tions (P=0.02 and P=0.006, respectively), while no signifi-
cant association was observed for marijuana use or regular
alcohol assumption. Notably, alcohol abuse was reported by
only three patients. Hobbies involving high exposure to fun-
gal agents were associated with invasive mold infections
M. Caira et al.
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Figure 1. Study flow chart. IFD:invasive fungal disease.
1,192 patients enrolled
in the study
Promyelocytic AML
106 patients
No intensive therapy
(support or low dose)
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881 patients
214 patients with
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191 patients with invasive
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Patients with POSSIBLE
MOLD infection
137 patients
23 patients with PROVEN invasive
YEAST infection
YEAST CASES
54 patients with
PROBABLE/PROVEN invasive
MOLD infection
MOLD CASES
667 patients
with NO evidence of IFD
CONTROLS
(18.5% in cases versus 8.7% in controls, P=0.017). A possible
correlation between invasive mold infections and jobs with
high exposure to fungal agents was also found (P=0.0001).
Among the working and living place factors, only a recent
house renovation (within the 6 months preceding the diag-
nosis of AML) was found to be more frequent in the mold
cases (24% versus 9.6%, P<0.001).
When considering post-treatment variables, we found an
increased risk of invasive mold infection in patients with
grade 3-4 esophagitis (Table 2). Systemic prophylaxis (with
any drug) resulted in protection from invasive mold infec-
tion onset. Posaconazole was the most frequently used drug
and it emerged as a protective factor (P=0.002). 
Pre- and post-chemotherapy variables were thus included
in a common multivariate model for evaluating the risk of
proven/probable invasive mold infections. As for pre-
chemotherapy variables, the analysis confirmed that a per-
formance status of 2 or greater (P<0.001), a recent house ren-
ovation (during the 6 months preceding the diagnosis of
AML) (P<0.001), higher body weight (P=0.012), job with
Pre-hospitalization risk factors for fungal infections
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Table 1A. Univariate analysis of the main PRE-chemotherapy risk factors for proven/probable invasive fungal infection. 
Variables Controls (n=667) Mold cases P value Yeast cases P value
(n=54) (n=23)
Demographic data
Gender
Male 340 (51%) 23 (42%) 0.23 8 (35%) 0.12
Female 327 (49%) 31 (58%) 15 (65%)
Age
≤50 years 217 (32.5%) 9 (17%) 0.015 18 (78%) 0.27
>50 years 450 (67.5%) 45 (83%) 5 (22%)
Race
Caucasian 660 (99%) 52 (96%) 0.09 23 (100%) 0.62
Other 7 (1%) 2 (4%) 0
Body weight
Lower/normal 483 (72%) 46 (85%) 0.04 18 (78%) 0.53
Higher 184 (28%) 8 (15%) 5 (22%)
Season of diagnosis
Winter/spring 370 (55.5%) 24 (44.5%) 0.11 5 (22%) 0.03
Summer/autumn 297 (44.5%) 30 (55.5%) 18 (78%)
Type of hospital
Teaching 405 (61%) 35 (65%) 0.55 16 (70%) 0.39
Non-teaching 262 (29%) 19 (35%) 7 (30%)
AML & treatment
Type of AML
Primary 497 (74.5%) 43 (80%) 0.40 5 (22%) 0.68
Secondary 170 (25.5%) 11 (20%) 18 (78%)
Fludarabine-containing regimen1
Yes 114 (22%) 9 (20%) 0.69 6 (32%) 0.33
No 402 (78%) 37 (80%) 13 (68%)
Comorbidities
Performance status2
0-1 509 (76%) 26 (48%) <0.001 6 (26%) 0.79
2-4 158 (24%) 28 (52%) 17 (74%)
Diabetes
Yes 43 (6.5%) 9 (17%) 0.005 2 (9%) 0.66
No 624 (93.5%) 45 (83%) 21 (91%)
Chronic renal failure
Yes 19 (3%) 3 (5%) 0.26 2 (9%) 0.1
No 648 (97%) 51 (95%) 21 (91%)
COPD
Yes 23 (3%) 6 (11%) 0.005 1 (4%) 0.81
No 644 (97%) 48 (89%) 22 (96%)
Chronic liver failure
Yes 29 (4%) 1 (2%) 0.37 3 (13%) 0.05
No 638 (96%) 53 (98%) 20 (87%)
AML: acute myeloid leukemia; COPD: chronic obstructive pulmonary disease. 1Data from 581 patients only. 2According to the ECOG scale.
high exposure (P=0.003) and COPD (P=0.012) significantly
influenced the onset of mold infections. Of the post-treat-
ment variables, three remained statistically significant:
posaconazole prophylaxis (protective factor, P=0.002) and
days of neutropenia and esophagitis (both risk factors,
P=0.042 and P=0.005, respectively) (Table 3). 
The logistic regression model exhibited good discrimina-
tion, with an area under the ROC curve of 0.77 (Figure 2). 
Yeast cases
Twenty-three patients with proven invasive yeast infec-
tions (yeast cases) were compared to 667 controls (Figure 1).
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Table 1B. Univariate analysis of the main PRE-chemotherapy risk factors for proven/probable invasive fungal infections.
Variables Controls  Mold cases P value Yeast cases P value
(n=667) (n=54) (n=23)
Personal habits
Cigarette smoking
Yes 196 (30%) 24 (44%) 0.020 8 (35%) 0.57
No 471 (70%) 30 (56%) 15 (65%)
Alcohol, regular assumption 
Yes 162 (25%) 19 (35%) 0.062 7 (30%) 0.5
No 505 (75%) 35 (65%) 16 (70%)
Cocaine use
Yes 7 (1%) 3 (6%) 0.006 1 (4%) 0.14
No 660 (99%) 51 (94%) 22 (96%)
Marijuana use
Yes 19 (3%) 1 (2%) 0.66 1 (4%) 0.67
No 648 (97%) 53 (98%) 22 (96%)
Type of hobbies *
High exposure 58 (9%) 10 (18.5%) 0.017 4 (17%) 0.15
Regular exposure 609 (91%) 44 (81.5%) 19 (83%)
Hunting 
Yes 14 (2%) 2 (4%) 0.44 2 (9%) 0.038
No 653 (98%) 36 (96%) 21 (91%)
Working & living places
Type of job *
High exposure 41 (6%) 11 (20%) 0.0001 1 (4%) 0.72
Regular exposure 626 (94%) 43 (80%) 22 (96%)
Type of house
Apartment 382 (57%) 26 (48%) 0.19 13 (56.5%) 0.94
House with garden 285 (43%) 28  (52%) 10 (43.5%)
Area of residence
Rural 190 (28.5%) 13 (24%) 0.48 8 (35%) 0.51
Urban 477 (71.5%) 41 (76%) 15 (65%)
Fireplace in house
Yes 207 (31%) 18 (33%) 0.73 7 (30%) 0.95
No 460 (69%) 36 (67%) 16 (70%)
Potted plants in house
Yes 398 (40%) 33 (61%) 0.83 13 (56%) 0.76
No 268 (60%) 21 (39%) 10 (44%)
House renovation^ 
Yes 64 (10%) 13 (24%) <0.001 1 (4%) 0.39
No 603 (90%) 41 (76%) 22 (96%)
Construction sites near home°
Yes 207 (31%) 19 (35%) 0.52 8 (35%) 0.7
No 460 (69%) 35 (65%) 15 (65%)
Pet ownership
Yes 239 (36%) 16 (30%) 0.35 7 (30%) 0.59
No 428 (64%) 38 (70%) 16 (70%)
Poultry ownership
Yes 60 (9%) 5 (9%) 0.94 3 (13%) 0.5
No 607 (91%) 49 (91%) 20 (87%)
* “High exposure” jobs included construction work, farming, gardening, working in a florist’s shop, and forestry work, according to reference 13. * “High exposure” hobbies
included hunting, gardening, fishing, and hiking, according to reference 13. ^During the 6 months preceding the diagnosis of AML. ° Within 600 meters.
Upon univariate analysis of pre-chemotherapy variables,
chronic liver disease and hunting were found to be more fre-
quent in the yeast cases than in the controls (Table 1A,B).
Post-chemotherapy risk factors that emerged as signifi-
cantly influencing the onset of invasive yeast infections were
the presence of a central venous catheter (P=0.03), grade 3-4
esophagitis (P<0.001), and grade 3-4 diarrhea (P=0.006)
(Table 2). Posaconazole prophylaxis significantly reduced
the incidence of yeast infections.  
The impact of esophagitis, posaconazole prophylaxis and
a central venous catheter in influencing the risk of yeast
infections was confirmed by multivariate analysis; however,
none of the pre-chemotherapy variables was shown to inde-
pendently influence the risk of invasive yeast infections,
according to the final multivariate model (Table 3). 
Discussion
Underlying hematologic malignancies and neutropenia
have been recognized as crucial risk factors for invasive fun-
gal infections.16,17 However, it is well known that only a few
patients among those considered at the highest risk (i.e.,
patients with AML) will develop an invasive fungal infec-
tion. With this in mind, it has been proven that many other
factors, both intrinsic and extrinsic, modifiable and not,
should be considered when defining a patient’s risk level.8
To our knowledge, this is the first prospective study ana-
lyzing the impact of potential risk factors for invasive fungal
infections at the time of the patients’ first admission. The
multicenter study allowed an analysis of a large cohort of
hematologic patients. Enrollment was limited to those
patients with newly diagnosed AML; furthermore, to
increase the homogeneity of our study population, we
excluded those patients who had not received either inten-
sive (hypomethylating agents, support) or highly myelosup-
pressive regimens (promyelocytic leukemia). 
In several previous studies, the first induction of remission
was proven to be the phase at which patients with AML
were at highest risk of invasive fungal infections.18 It has,
therefore, been speculated that pre-hospital exposure to
fungi may play a role in invasive fungal infections. However,
while the crucial role of the patient’s environment during
hospitalization has been clearly demonstrated, the role of
the environment outside the hospital is more difficult to
evaluate.19,20 We assumed that some variables (location of
residence, type of house, presence of potted plants, etc.) may
be a surrogate indicator of the patient’s exposure to spores in
the air.21 Not surprisingly, we found a strong correlation (con-
firmed by multivariate analysis) between a recent house ren-
ovation and the onset of an invasive mold infection. This is
congruent with reports of outbreaks of invasive aspergillosis
during construction work in hospitals.20
Pet ownership has been traditionally associated with fun-
gal zoonoses.22,23 For this reason, we analyzed the risk of pet
owners and hunters in particular, but neither of these vari-
Pre-hospitalization risk factors for fungal infections
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Table 2. Univariate analysis of the main POST-chemotherapy risk factors for proven/probable invasive fungal infections. 
Variables Controls (n=667) Mold cases (n=54) P value Yeast cases (n=23) P value
Mucosal damage & medical devices
Profound neutropenia
Yes 661 (99%) 53 (98%) 0.49 23 (100%) 0.64
No 6 (1%) 1 (2%) 0
Days of neutropenia 19±9 23±9 0.10 20±8 0.28
(mean ± SD)
Mucositis grade ≥2*
Yes 262 (39%) 28 (52%) 0.07 13 (56%) 0.09
No 405 (61%) 26 (48%) 10 (44%)
Esophagitis grade >2*
Yes 46 (7%) 8 (15%) 0.03 6 (26%) <0.001
No 621 (93%) 46 (85%) 17 (74%)
Diarrhea grade >2*
Yes 176 (26%) 18 (33%) 0.27 12 (52%) 0.006
No 491 (74%) 36 (67%) 11 (48%)
Vomiting
Yes 139 (21%) 14 (26%) 0.37 8 (35%) 0.10
No 528 (79%) 40 (74%) 15 (65%)
Central venous catheter
Yes 511 (77%) 39 (72%) 0.46 22 (96%) 0.03
No 156 (23%) 15 (28%) 1 (4%)
Antifungal prophylaxis
Systemic prophylaxis
- Yes 643 (96.4%) 49 (91%) 0.041 20 (87%) 0.02
- No 24 (3.6%) 5 (9%) 3 (13%)
Posaconazole prophylaxis
- Yes 411 (61.6%) 22 (41%) 0.002 6 (26%) <0.001
- No 256 (38.4%) 32 (59%) 17 (74%)
Standard deviation. * According to the WHO.
ables emerged as a significant risk factor for invasive fungal
infections in our cohort.24
Patients are generally advised against gardening and other
activities exposing them to dust that may contain spores,
even though the role of such activities has never been
proven. In our analysis “high exposure” hobbies and jobs
were more frequent in patients with invasive mold infec-
tions. It can be speculated that such activities may have led
to mold colonization in the patients prior to their hospital-
ization. 
In a study by Panackal et al., it was found that the inci-
dence of invasive aspergillosis was higher during the sum-
mer and autumn.25 This seasonal difference in incidence did
not emerge in our series, in which invasive mold infections
were equally distributed throughout the year. In contrast, a
higher proportion of yeast cases occurred during the sum-
mer and autumn. 
Specific personal habits relating to exposure were also
investigated. In a previous similar study, a sub-analysis of a
small subgroup of AML patients revealed them to be at high-
er risk if they were cigarette smokers.21 Both tobacco and
cannabis contain fungal spores that may contaminate the
lower respiratory tract.26,27 In addition, nicotine has marked
effects on the immune response system and has been report-
ed to inhibit the release of some cytokines (e.g., interleukin-
6, tumor necrosis factor-a) and to depress the functions of
murine alveolar macrophages.28,29 In our experience, there
was an association between smoking and invasive mold
infections only in the univariate analysis. Similarly, alcohol is
known to have multiple effects on host immune responses,
including depletion of circulating lymphocytes and reduc-
tion of the Th1 cytokine response, which is protective
against microbial infections,30,31 but we did not find any cor-
relation between alcohol and invasive fungal infections in
our study. 
Smoking marijuana has been reported to be associated
with pulmonary aspergillosis because of the possible con-
tamination of the leaves by Aspergillus spp.32,33 This correla-
tion was not confirmed in our series, most likely due to the
very low number of patients reporting marijuana use. In
contrast, cocaine emerged as a possible risk factor for inva-
sive mold infections in the univariate analysis. The effects of
this drug on immunity have been extensively investigated,
mainly in murine models and in vitro studies. Nearly all of
these studies have shown a correlation with reduced
immune function, including both cellular and humoral
immunity.31
Performance status and comorbid conditions can easily be
evaluated at the time of first admission. Diabetes is a well-
known risk factor for mucormycosis, but it has never been
investigated in patients with invasive aspergillosis, nor in a
prospective study of a large cohort of patients.34,35 In our
analysis, diabetes was more frequent in mold cases, suggest-
ing a potential role as an additional risk factor for all invasive
mold infections. Patients with severe COPD who receive
broad-spectrum antibiotics and corticosteroids are becoming
one of the main risk groups for invasive pulmonary
aspergillosis.36 However, the role of COPD as a potential
additional risk factors in hematologic patients has never
been investigated before. In our study, both univariate and
multivariate analyses confirmed COPD as an additional risk
factor in AML patients.
In the last few years, an association between liver failure
and invasive aspergillosis has been suspected.37,38 Because
patients with AML have abnormal cellular and humoral
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Table 3. Multivariate analysis of the PRE- and POST-chemotherapy risk factors for proven/probable invasive mold infections and proven yeast
infections. 
Proven/probable mold infection Proven yeast infection
VARIABLES OR P value 95% CI OR P value 95% CI 
Pre-chemotherapy
Performance status ≥2* 3.10 <0.001 1.69-5.67 --- --- ---
House renovation 4.01 <0.001 1.89-8.52
Higher body weight 0.34 0.012 0.15-0.79 --- --- ---
High exposure job 3.43 0.003 1.52-7.70 --- --- ---
COPD 3.96 0.012 1.35-11.55 --- --- ---
Post-chemotherapy
Days of neutropenia 1.03 0.042 1-1.06 --- --- ---
Esophagitis grade >2** 3.52 0.005 1.45-8.57 4.24 0.013 1.35-13.3
Central venous catheter --- --- --- 7.25 0.058 0.93-56
Posaconazole prophylaxis 0.37 0.002 0.20-0.69 0.22 0.006 0.08-0.65
COPD: chronic obstructive pulmonary disease. * According to the ECOG scale. ** According to the WHO scale
Figure 2. Receiver-operator characteristic (ROC) curve for the multi-
variate model for invasive mold infections.
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immunity, they may be unable to eliminate inhaled conidia,
and this may predispose them to invasive aspergillosis.39 Our
study did not confirm such an association, but this may be
related to the very low number of patients reporting a histo-
ry of hepatic disease. Renal dysfunction has been reported to
be a risk factor for invasive aspergillosis in lung transplant
recipients.40 This relationship did not emerge from our analy-
sis. 
Surprisingly, we found that patients with a higher body
mass index were protected from invasive mold infections
and that this relationship was highly significant upon multi-
variate analysis. Some smaller studies have shown that
obese subjects may have an altered response to sepsis. Some
investigations have focused on hormonal mediators, includ-
ing leptin and adiponectin, showing that their levels are
altered.41,42 Both these alterations were correlated with
human survival of sepsis, although the relationships were
complex and the studies involved few patients. 
Hospital- and treatment-dependent risk factors were also
analyzed because they are potentially confounding variables
in our analysis. It was impossible to prove the role of severe
neutropenia in either mold or yeast infections because all
patients received intensive chemotherapy and were, thus, all
profoundly neutropenic. However, an association between
the duration of neutropenia and the risk of invasive mold
infections was confirmed. 
In a recent single center analysis conducted at the M.D.
Anderson Cancer Center involving 165 patients with AML,
those receiving investigational clofarabine-containing proto-
cols and those with therapy-related disease were at higher
risk of invasive fungal infections, with the effect of clofara-
bine-containing protocols being confirmed in the multivari-
ate analysis.43 Both these variables were included in our
analysis, but neither resulted predictive of the onset of inva-
sive fungal infections. 
The protective role of posaconazole prophylaxis in high-
risk patients has been demonstrated in several clinical trials
and confirmed in clinical experience.4-6,44 According to these
previous results, posaconazole prophylaxis resulted in a sig-
nificantly reduced incidence of mold infections.6 The higher
number of patients in the present analysis allowed us to
prove the protective role of posaconazole against yeast
infections as well.  
Post-treatment variables were the only variables that were
significantly related to yeast cases in the multivariate analy-
sis. This is likely because of the differing pathogenesis of
yeast infections, which are related to mucosal damage rather
than to entrance via the respiratory system. 
In conclusion, our study indicates several chemotherapy-
independent risk factors for mold infections in patients with
AML; these risk factors include hospital-independent expo-
sure to infectious agents, comorbidities and personal habits.
The recognition of these factors at the time of admission
may be useful to define a patient’s risk category better and
to improve targeted prophylactic, diagnostic and therapeutic
measures. Assessing the coexistence of these risk factors to
anticipate the risk of invasive mold infections may be feasi-
ble and useful for all centers, particularly those with limited
resources. 
Acknowledgments
Other contributors (SEIFEM Group): Annarosa Cuccaro, Giulia
Dragonetti, Università Cattolica del Sacro Cuore, Roma; Marta
Stanzani, Riccardo Ragionieri, Istituto di Ematologia ed Oncologia
Clinica “Lorenzo e Ariosto Serágnoli,” Ospedale S.Orsola-
Malpighi, Università di Bologna; Francesca Antoniazzi, Div. di
Ematologia-Spedali Civili Brescia; Sergio Storti, Università
Cattolica del Sacro Cuore, Campobasso; Mario Luppi,
Dipartimento di Oncologia ed Ematologia, Università di Modena e
Reggio Emilia, Azienda Ospedaliera Policlinico, Modena; Simona
Pagliuca, Azienda Ospedaliera Universitaria Federico II Napoli,
Dipartimento di Medicina Clinica e Chirurgia; Elena Rossetti,
Sezione di Ematologia, Università di Parma; Matteo Da Vià,
Dipartimento Onco-Ematologico, Fondazione ICRRS Policlinico
San Matteo, Pavia; Luigi Di Caprio, Unità di Ematologia,
Università Tor Vergata, Roma; Ignazio Majolino, Divisione di
Ematologia, Ospedale S. Camillo, Roma; Nicola Cascavilla,
Divisione di Ematologia, IRCCS Ospedale S. Giovanni Rotondo;
Gloria Turri, UOC Ematologia, Azienda Ospedaliera
Universitaria Integrata di Verona; Renato Fanin, Clinica di
Ematologia, Università di Udine.
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
Pre-hospitalization risk factors for fungal infections
haematologica | 2015; 100(2) 291
References
1. Pagano L, Caira M, Picardi M, et al. Invasive
aspergillosis in patients with acute
leukemia: update on morbidity and mortali-
ty--SEIFEM-C Report. Clin Infect Dis. 2007;
44(11):1524-1525.
2. Perkhofer S, Lass-Flörl C, Hell M, et al. The
Nationwide Austrian Aspergillus Registry: a
prospective data collection on epidemiology,
therapy and outcome of invasive mould
infections in immunocompromised and/or
immunosuppressed patients. Int J
Antimicrob Agents. 2010;36(6):531-536. 
3. Even C, Bastuji-Garin S, Hicheri Y, et al.
Impact of invasive fungal disease on the
chemotherapy schedule and event-free sur-
vival in acute leukemia patients who sur-
vived fungal disease: a case-control study.
Haematologica. 2011;96(2):337-341. 
4. Cornely OA, Maertens J, Winston DJ, et al.
Posaconazole vs. fluconazole or itracona-
zole prophylaxis in patients with neutrope-
nia. N Engl J Med. 2007;356(4):348-359. 
5. Ullmann AJ, Lipton JH, Vesole DH, et al.
Posaconazole or fluconazole for prophylaxis
in severe graft-versus-host disease. N Engl J
Med. 2007;356(4):335-347. 
6. Pagano L, Caira M, Candoni A, et al.
Evaluation of the practice of antifungal pro-
phylaxis use in patients with newly diag-
nosed acute myeloid leukemia: results from
the SEIFEM 2010-B registry. Clin Infect Dis.
2012;55(11):1515-1521. 
7. Georgiadou SP, Kontoyiannis DP. The impact
of azole resistance on aspergillosis guidelines.
Ann NY Acad Sci. 2012; 1272:15-22. 
8. Pagano L, Akova M, Dimopoulos G,
Herbrecht R, Drgona L, Blijlevens N. Risk
assessment and prognostic factors for
mould-related diseases in immunocompro-
mised patients. J Antimicrob Chemother
2011;66(S1):i5-14. 
9. Oren I, Haddad N, Finkelstein R, Rowe JM.
Invasive pulmonary aspergillosis in neu-
tropenic patients during hospital construc-
tion: before and after chemoprophylaxis and
institution of HEPA filters. Am J Hematol.
2001;66(4):257-262.
10. Flynn PM, Williams BG, Hetherington SV,
Williams BF, Giannini MA, Pearson TA.
Aspergillus terreus during hospital renova-
tion. Infect Control Hosp Epidemiol. 1993;
14(7):363-365.
11. de Pauw B, Walsh TJ, Donnelly JP, et al.
Revised definitions of invasive fungal dis-
ease from the European Organization for
Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and
the National Institute of Allergy and
Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group. Clin
Infect Dis. 2008;46(12):1813-1821.
12. Parulekar W, Mackenzie R, Bjarnason G,
Jordan RC. Scoring oral mucositis. Oral
Oncol. 1998;34(1):63-71. 
13. Sipsas NV, Kontoyiannis DP. Occupation,
lifestyle, diet, and invasive fungal infections.
Infection. 2008;36(6):515-525.
14. Kuperman EF, Showalter JW, Lehman EB,
Leib AE, Kraschnewski JL. The impact of
obesity on sepsis mortality: a retrospective
review. BMC Infect Dis. 2013;13(1):377. 
15. Oken MM, Creech RH, Tormey DC, et al.
Toxicity and response criteria of the Eastern
Cooperative Oncology Group. Am J Clin
Oncol. 1982;5(6):649-655.
16. Bodey GP. The changing face of febrile neu-
tropenia-from monotherapy to moulds to
mucositis. Fever and neutropenia: the early
years. J Antimicrob Chemother. 2009;
63(S1):i3-13. 
17. Pagano L, Caira M, Candoni A, et al. The
epidemiology of fungal infections in patients
with hematologic malignancies: the
SEIFEM-2004 study. Haematologica. 2006;
91(8):1068-1075.
18. Pagano L, Caira M, Candoni A, et al.
Invasive aspergillosis in patients with acute
myeloid leukemia: SEIFEM-2008 registry
study. Haematologica. 2010;95(4):644-650.
19. Cristina ML, Sartini M, Spagnolo AM.
Health care-acquired aspergillosis and air
conditioning systems. J Prev Med Hyg. 2009;
50(1):3-8. 
20. Weber DJ, Peppercorn A, Miller MB,
Sickbert-Benett E, Rutala WA. Preventing
healthcare-associated Aspergillus infections:
review of recent CDC/HICPAC recommen-
dations. Med Mycol. 2009;47(S1):199-209. 
21. Blum G, Eschertzhuber S, Auberger J, et al.
Airborne fungus exposure prior to hospitali-
sation as risk factor for mould infections in
immunocompromised patients. Mycoses.
2012;55(3):237-243. 
22. Litwin CM. Pet-transmitted infections: diag-
nosis by microbiologic and immunologic
methods. Pediatr Infect Dis J. 2003;22(9):
768-777. 
23. Schubach A, Schubach TM, Barros MB,
Wanke B. Cat-transmitted sporotrichosis,
Rio de Janeiro, Brazil. Emerg Infect Dis.
2005;11(12):1952-1954.
24. Armstrong CW, Jenkins SR, Kaufman L,
Kerkering TM, Rouse BS, Miller GB Jr.
Common-source outbreak of blastomycosis
in hunters and their dogs. J Infect Dis. 1987;
155(3):568-570. 
25. Panackal AA, Li H, Kontoyiannis DP, et al.
Geoclimatic influences on invasive
aspergillosis after hematopoietic stem cell
transplantation. Clin Infect Dis. 2010;
50(12):1588-1597. 
26. Verweij PE, Kerremans JJ, Voss A, Meis JF.
Fungal contamination of tobacco and mari-
juana. JAMA. 2000;284(22):2875. 
27. Szyper-Kravitz M, Lang R, Manor Y, Lahav
M. Early invasive pulmonary aspergillosis in
a leukemia patient linked to aspergillus con-
taminated marijuana smoking. Leuk
Lymphoma. 2001;42(6):1433-1437. 
28. Sopori M. Effects of cigarette smoke on the
immune system. Nat Rev Immunol. 2002;
2(5):372-377. 
29. Ouyang Y, Virasch N, Hao P, et al.
Suppression of human IL-1beta, IL-2, IFN-
gamma, and TNF-alpha production by ciga-
rette smoke extracts. J Allergy Clin
Immunol. 2000; 106(2):280-7. 
30. Szabo G, Mandrekar P. A recent perspective
on alcohol, immunity, and host defense.
Alcohol Clin Exp Res. 2009;33(2):220-232. 
31. Friedman H, Pross S, Klein TW. Addictive
drugs and their relationship with infectious
diseases.  FEMS Immunol Med Microbiol.
2006;47(3):330-342. 
32. Levitz SM, Diamond RD. Aspergillosis and
marijuana. Ann Intern Med. 1991;115(7):
578-579.
33. Gargani Y, Bishop P, Denning DW. Too
many mouldy joints - marijuana and chronic
pulmonary aspergillosis. Mediterr J Hematol
Infect Dis. 2011;3(1):e2011005.
34. Caira M, Trecarichi EM, Mancinelli M,
Leone G, Pagano L. Uncommon mold infec-
tions in hematological patients: epidemiolo-
gy, diagnosis and treatment. Expert Rev Anti
Infect Ther. 2011;9(7):881-892.
35. Rammaert B, Lanternier F, Poirée S, Kania R,
Lortholary O. Diabetes and mucormycosis:
a complex interplay. Diabetes Metab. 2012;
38(3):193-204. 
36. Guinea J, Torres-Narbona M, Gijón P, et al.
Pulmonary aspergillosis in patients with
chronic obstructive pulmonary disease: inci-
dence, risk factors, and outcome. Clin
Microbiol Infect. 2010;16(7):870-877. 
37. Wang W, Zhao CY, Zhou JY, et al. Invasive
pulmonary aspergillosis in patients with
HBV-related liver failure. Eur J Clin
Microbiol Infect Dis. 2011;30(5):661-667. 
38. Li D, Chen L, Ding X, Tao R, Zhang YX,
Wang JF. Hospital-acquired invasive pul-
monary aspergillosis in patients with hepatic
failure. BMC Gastroenterol. 2008;8:32. 
39. Cheruvattath R, Balan V. Infections in
patients with end-stage liver disease. J Clin
Gastroenterol. 2007;41(4):403-411. 
40. Gordon SM, Avery RK. Aspergillosis in lung
transplantation: incidence, risk factors, and
prophylactic strategies. Transpl Infect Dis.
2001;3(3):161-167. 
41. Bornstein SR, Licinio J, Tauchnitz R, et al.
Plasma leptin levels are increased in sur-
vivors of acute sepsis: associated loss of
diurnal rhythm, in cortisol and leptin secre-
tion. J Clin Endocrinol Metab. 1998;83(1):
280-283. 
42. Walkey AJ, Rice TW, Konter J, et al. Plasma
adiponectin and mortality in critically ill sub-
jects with acute respiratory failure. Crit Care
Med. 2010;38(12):2329-2334. 
43. Gomes M, Mulanovich V, Ying J, Lewis R,
Kontoyiannis D. Risk factors for invasive
fungal infections in acute myeloid leukaemia
patients during primary antifungal prophy-
laxis at M.D. Anderson Cancer Center,
2009-2011. Poster P1002. 23rd ECCMID.
Berlin 27-30 April 2013.  
44. Pagano L, Caira M, Cuenca-Estrella M. The
management of febrile neutropenia in the
posaconazole era: a new challenge?
Haematologica. 2012;97(7):963-965.
M. Caira et al.
292 haematologica | 2015; 100(2)
